Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
Cytochrome P450 gene-directed enzyme prodrug therapy substantially augments intratumoral activation of anticancer prodrugs, such as cyclophosphamide (CPA), leading to a strong increase in antitumor effect without a corresponding increase in host toxicity. Attempts to additionally increase tumor cell kill by enhancing the intrinsic chemosensitivity of P450-expressing tumor cells by chemical means (depletion of cellular glutathione) or by coexpression of proapoptotic factors was shown to result in the desired increase in chemosensitivity, but with a decrease in net production of bystander cytotoxic drug metabolites because of accelerated death of the prodrug-activating tumor cells. Moreover, tumor cell P450 activity declined during the course of apoptosis induced by P450-activated CPA, limiting the potential of the tumor cell for continued production of activated drug metabolites. This limitation could be overcome by retroviral delivery of the baculovirus-encoded caspase inhibitor p35 to P450-expressing tumor cells. p35 substantially prolonged the activation of CPA by P450 "factory cells," leading to an increase in their bystander cytotoxicity toward P450-deficient tumor cells. This effect was greatest in tumor cells treated with CPA for an 8-h period, a schedule designed to model the effective time period of drug exposure in bolus CPA-treated patients in vivo. Notably, retroviral transduction of tumor cells with p35 did not induce drug resistance, as shown by the absence of long-term tumor cell survival or detectable colony formation activity after CPA treatment. These findings demonstrate that antiapoptotic factors, such as p35, can be used in a novel manner to enhance prodrug activation gene therapy by delaying tumor cell death, thereby increasing the net production of bystander cytotoxic metabolites and, hence, the overall effectiveness of the anticancer strategy.
Schwartz
Pamela S
PS
Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts 02215, USA.
Chen
Chong-Sheng
CS
Waxman
David J
DJ
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D001711:Biotransformation; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D004789:Enzyme Activation; D015316:Genetic Therapy / Q000379:methods*; D018316:Gliosarcoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D005978:Glutathione / Q000172:deficiency / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D009251:NADPH-Ferrihemoprotein Reductase / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D011355:Prodrugs / Q000493:pharmacokinetics*; D051381:Rats; D014407:Tumor Cells, Cultured; D014764:Viral Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism
D061945:Caspase Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D011355:Prodrugs; D014764:Viral Proteins; C086430:inhibitor of apoptosis, Nucleopolyhedrovirus; D003520:Cyclophosphamide; D003577:Cytochrome P-450 Enzyme System; D009251:NADPH-Ferrihemoprotein Reductase; D020169:Caspases; D005978:Glutathione; C011272:perfosfamide